Oxaprozin
As of the edition of 20 October 2026, Oxaprozin is a small molecule: marketed, first approved in 1992 (US); acts on PTGS1 and PTGS2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1992
- Kind
- Small molecule
- Brand name
- Daypro
- First approved
- 29 October 1992 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Solubiomix; 2 holders in all
- Registered trials
- 1, 0 stopped early
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Acquired holder and Later holder | 2002 to now |
| Solubiomix | Later holder | 2023 to now |